Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
CORALVILLE, Iowa, Jan. 04, 2017 -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis Mickle, Ph.D., will present at Biotech Showcase 2017 to be held January 9-11, 2017, at the Hilton San Francisco Union Square.
Details of KemPharm's presentation are as follows:
| Event: | Biotech Showcase 2017 | |
| Date: | Tuesday, January 10, 2017 | |
| Time: | 3:00 p.m. (Pacific Time) | |
| Location: | Hilton San Francisco Union Square |
The presentation will be webcast and available on the Investor Relations section of the KemPharm website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other central nervous system (CNS) disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release (ER) prodrug of methylphenidate for the treatment of attention deficit hyperactivity disorder (ADHD), and KP201/IR, an acetaminophen (APAP)-free formulation of the company’s immediate release (IR) abuse deterrent hydrocodone product, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
